Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 2 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Cyclacel Pharmaceuticals, Inc.
January 1, 2011 By Leave a Comment
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. The Company has three orally-available product candidates in clinical development, for which Cyclacel has retained rights in most global markets. Through Cyclacel’s ALIGN Pharmaceuticals subsidiary, the Company markets Xclair® [...]
Investment Opportunities with Five Frontline Therapies for AML
September 6, 2010 By 2 Comments
Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]
Biotech Deal Activity Declines…The Pause that Refreshes?
January 14, 2010 By 1 Comment
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]
Follow MD Becker Partners